Power-Laws and the Use of Pluripotent Stem Cell Lines

Bernhard M Schuldt, Anke Guhr, Michael Lenz, Sabine Kobold, Ben D MacArthur, Andreas Schuppert, Peter Löser and Franz-Josef Müller

PLOS ONE, 2013, vol. 8, issue 1, 1-9

Abstract: It is widely accepted that the (now reversed) Bush administration’s decision to restrict federal funding for human embryonic stem cell (hESC) research to a few “eligible” hESC lines is responsible for the sustained preferential use of a small subset of hESC lines (principally the H1 and H9 lines) in basic and preclinical research. Yet, international hESC usage patterns, in both permissive and restrictive political environments, do not correlate with a specific type of stem cell policy. Here we conducted a descriptive analysis of hESC line usage and compared the ability of policy-driven processes and collaborative processes inherent to biomedical research to recapitulate global hESC usage patterns. We find that current global hESC usage can be modelled as a cumulative advantage process, independent of restrictive or permissive policy influence, suggesting a primarily innovation-driven (rather than policy-driven) mechanism underlying human pluripotent stem cell usage in preclinical research.

Date: 2013
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0052068 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 52068&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0052068

DOI: 10.1371/journal.pone.0052068

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().